A variety of such strategies involving the targeting of YAP/TAZ activity have been described in the past, including the leveraging of approved, clinically established drugs such as the AMPK agonist metformin and the statin family of HMG-CoA reductase (HMGCR) inhibitors, classically used to treat hypercholesterolaemia. Here, HMGCR is linked to Hypercholesterolemia.